Monopar Therapeutics Inc Financials

MNPR

FY2025 annual

Revenue $0 YoY not available

Net Income -$13.7M +12.0% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Monopar Therapeutics Inc (MNPR) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MNPR FY2025 2026-08-30

Monopar operates as a research-funded development company: external financing expands its asset base while operating activities remain cash-consuming.

In FY2025, financing supplied $91.6M while investing absorbed $63.5M, indicating that balance-sheet expansion was funded externally rather than by business-generated receipts. Operating cash flow was -$12.2M, so the company’s cash-flow architecture combines funding inflows with continuing investment and operating consumption.

With no reported revenue, the expense base is the operating model: FY2025 research and development plus selling, general, and administrative spending totaled $16.7M, approximately matching the operating loss. R&D remained a major use of resources, while SG&A increased materially from FY2024, showing that the loss reflects both scientific investment and corporate infrastructure.

The balance sheet became much larger without becoming similarly leveraged: FY2025 liabilities were only $2.9M against $140.7M of assets, leaving the company predominantly equity-funded. A 51.4x current ratio reinforces that short-term obligations are small relative to reported current assets, while the reported $35.0M of share buybacks occurred alongside substantial financing activity.

Financial Health Signals

Financial health score not available

Monopar Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

155.81

Monopar Therapeutics Inc scores 155.81, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($751.0M) relative to total liabilities ($2.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Monopar Therapeutics Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Monopar Therapeutics Inc reported a net loss of $13.7M while operations used $12.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Monopar Therapeutics Inc generated $0 in revenue in fiscal year 2025.

Net Income

-$13.7M

YoY+12.0%

Monopar Therapeutics Inc reported -$13.7M in net income in fiscal year 2025. This represents an increase of 12.0% from the prior year.

EBITDA

Not reported for fiscal year 2025.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$61.8M

YoY+35.0%

5Y CAGR+29.9%

Monopar Therapeutics Inc held $61.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

YoY+9.5%

Monopar Therapeutics Inc had 7M shares outstanding in fiscal year 2025. This represents an increase of 9.5% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-10.0%

YoY+18.4pp

5Y CAGR+30.2pp

Monopar Therapeutics Inc's ROE was -10.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 18.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$9.9M

YoY-23.8%

5Y CAGR+19.5%

Monopar Therapeutics Inc invested $9.9M in research and development in fiscal year 2025. This represents a decrease of 23.8% from the prior year.

Share Buybacks

$35.0M

Monopar Therapeutics Inc spent $35.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

Not reported for fiscal year 2025.

MNPR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MNPR quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	N/A	$0	$0	N/A	N/A	N/A	N/A	$0	$0	$0	$0
R&D Expenses	N/A	$9.9M-23.8%	$13.0M+132.2%	$5.6M-26.2%	$7.6M+16.9%	$6.5M+59.7%	$4.1M+106.5%	$2.0M+10.9%	$1.8M+89.7%	$935K+233.6%	$280K
SG&A Expenses	N/A	$6.8M+115.5%	$3.2M-2.3%	$3.2M+9.7%	$2.9M+11.8%	$2.6M+7.8%	$2.4M+3.8%	$2.4M+51.3%	$1.6M+33.5%	$1.2M+27.8%	$912K
Operating Income	N/A	-$16.7M-3.4%	-$16.2M-83.0%	-$8.8M+16.2%	-$10.5M-15.4%	-$9.1M-40.2%	-$6.5M-50.5%	-$4.3M-29.8%	-$3.3M+79.9%	-$16.6M-1291.9%	-$1.2M
Interest Expense	N/A	N/A	N/A	$429K+1920.1%	$21K-11.6%	$24K-70.7%	$82K-17.2%	$99K-4.2%	$103K+113.9%	$48K+567.2%	$7K
Income Tax	N/A	$8000.0%	$8000.0%	$8000.0%	$800	$0-100.0%	$18K	$0+100.0%	-$71K-1890.3%	-$4K-544.8%	$800
Net Income	N/A	-$13.7M+12.0%	-$15.6M-85.5%	-$8.4M+20.1%	-$10.5M-15.5%	-$9.1M-44.4%	-$6.3M-49.2%	-$4.2M-30.9%	-$3.2M+80.5%	-$16.6M-1296.3%	-$1.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.8M+36.7%	$3.5M	N/A	$2.6M+49.7%	$1.7M+5.3%	$1.6M	N/A	$984K
SG&A Expenses	$1.9M+8.0%	$1.7M	N/A	$1.5M-0.1%	$1.5M-4.7%	$1.6M	N/A	$591K
Operating Income	-$6.6M-27.2%	-$5.2M	N/A	-$4.1M-26.6%	-$3.2M-0.4%	-$3.2M	N/A	-$1.6M
Net Income	-$5.3M-36.5%	-$3.9M	N/A	-$3.4M-40.1%	-$2.5M+6.5%	-$2.6M	N/A	-$1.3M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax, EPS (Diluted).

MNPR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MNPR quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$140.7M+133.4%	$60.3M+720.8%	$7.3M-44.5%	$13.2M-35.5%	$20.5M+21.7%	$16.9M+26.3%	$13.4M+82.5%	$7.3M-26.3%	$9.9M+243.0%	$2.9M
Current Assets	$140.5M+133.0%	$60.3M+722.2%	$7.3M-44.3%	$13.2M-35.8%	$20.5M+22.2%	$16.8M+27.0%	$13.2M+82.4%	$7.3M-20.6%	$9.1M+335.8%	$2.1M
Cash & Equivalents	$61.8M+35.0%	$45.8M+530.6%	$7.3M-11.2%	$8.2M-59.7%	$20.3M+21.3%	$16.7M+26.7%	$13.2M+91.7%	$6.9M-23.3%	$9.0M+333.4%	$2.1M
Total Liabilities	$2.9M-45.0%	$5.3M+199.0%	$1.8M-44.0%	$3.1M+98.5%	$1.6M+34.3%	$1.2M+62.5%	$724K+81.2%	$400K+28.1%	$312K+383.4%	$65K
Current Liabilities	$2.7M-47.9%	$5.3M+199.0%	$1.8M-43.8%	$3.1M+98.0%	$1.6M+34.3%	$1.2M+62.5%	$724K+81.2%	$400K+28.1%	$312K+383.4%	$65K
Total Equity	$137.8M+150.4%	$55.0M+885.0%	$5.6M-44.6%	$10.1M-46.7%	$18.9M+20.7%	$15.7M+24.3%	$12.6M+82.5%	$6.9M-28.1%	$9.6M+239.8%	$2.8M
Retained Earnings	-$89.5M-18.1%	-$75.8M-25.9%	-$60.2M-16.2%	-$51.8M-25.5%	-$41.3M-28.3%	-$32.2M-24.4%	-$25.9M-19.5%	-$21.7M-17.5%	-$18.4M-883.9%	-$1.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$135.0M-2.2%	$138.0M-1.9%	$140.7M-2.4%	$144.2M+167.7%	$53.9M-2.2%	$55.1M-8.6%	$60.3M+893.3%	$6.1M
Current Assets	$134.8M-2.2%	$137.7M-1.9%	$140.5M-2.5%	$144.1M+168.1%	$53.7M-2.4%	$55.1M-8.6%	$60.3M+893.3%	$6.1M
Cash & Equivalents	$52.8M+0.4%	$52.5M-15.0%	$61.8M-51.6%	$127.7M+223.2%	$39.5M-0.5%	$39.7M-13.3%	$45.8M+661.1%	$6.0M
Total Liabilities	$4.1M+59.3%	$2.6M-10.4%	$2.9M+9.5%	$2.6M+58.6%	$1.7M+11.5%	$1.5M-71.6%	$5.3M+367.9%	$1.1M
Current Liabilities	$4.0M+63.4%	$2.5M-10.1%	$2.7M+6.5%	$2.6M+62.2%	$1.6M	N/A	$5.3M	N/A
Total Equity	$130.9M-3.4%	$135.4M-1.8%	$137.8M-2.6%	$141.6M+171.2%	$52.2M-2.6%	$53.6M-2.6%	$55.0M+1012.6%	$4.9M
Retained Earnings	-$98.7M-5.7%	-$93.4M-4.3%	-$89.5M-6.2%	-$84.3M-4.3%	-$80.9M-3.1%	-$78.4M-3.5%	-$75.8M-16.8%	-$64.9M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

MNPR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MNPR quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$12.2M	-$12.2M-90.5%	-$6.4M+18.5%	-$7.9M-8.7%	-$7.2M+1.2%	-$7.3M-56.9%	-$4.7M-54.5%	-$3.0M-12.6%	-$2.7M-2.0%	-$2.6M-119.9%	-$1.2M
Investing Cash Flow	-$65.8M	-$63.5M-342.5%	-$14.3M-391.0%	$4.9M+200.2%	-$4.9M	$0	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$91.2M	$91.6M+54.4%	$59.3M+2824.8%	$2.0M+6066.8%	$33K-99.7%	$10.9M+33.0%	$8.2M-12.5%	$9.3M+4631.6%	-$206K-102.2%	$9.5M+655.4%	$1.3M
Share Buybacks	N/A	$35.0M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.2M+6.5%	-$3.5M-3.1%	-$3.4M-61.2%	-$2.1M-94.0%	-$1.1M+81.0%	-$5.7M-183.4%	-$2.0M-86.2%	-$1.1M
Investing Cash Flow	$4.1M+173.7%	-$5.6M+91.0%	-$62.2M-2825.1%	-$2.1M-279.1%	$1.2M+464.4%	-$326K+97.7%	-$14.3M-1554.6%	$986K
Financing Cash Flow	-$647K-223.4%	-$200K+48.0%	-$385K-100.4%	$92.4M+29259.9%	-$317K-173.9%	-$116K-100.2%	$56.1M+339623.6%	-$17K
Share Buybacks	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

MNPR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

MNPR quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Return on Equity	-10.0%+18.4pp	-28.3%+122.0pp	-150.4%-46.1pp	-104.2%-56.2pp	-48.1%-7.9pp	-40.2%-6.7pp	-33.5%+13.2pp	-46.7%+125.4pp	-172.1%-130.2pp	-41.9%
Return on Assets	-9.8%+16.1pp	-25.9%+88.5pp	-114.4%-34.9pp	-79.5%-35.1pp	-44.4%-7.0pp	-37.4%-5.7pp	-31.6%+12.5pp	-44.1%+122.6pp	-166.7%-125.7pp	-40.9%
Current Ratio	51.35+39.9x	11.47+7.3x	4.170.0x	4.21-8.8x	12.98-1.3x	14.28-4.0x	18.27+0.1x	18.15-11.1x	29.28-3.2x	32.48
Debt-to-Equity	0.02-0.1x	0.10-0.2x	0.310.0x	0.31+0.2x	0.080.0x	0.070.0x	0.060.0x	0.060.0x	0.030.0x	0.02

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-4.1%-1.2pp	-2.9%	N/A	-2.4%+2.3pp	-4.7%+0.2pp	-4.9%	N/A	-26.4%
Return on Assets	-3.9%-1.1pp	-2.8%	N/A	-2.4%+2.2pp	-4.5%+0.2pp	-4.8%	N/A	-21.5%
Current Ratio	33.56-22.5x	56.04+4.7x	51.35-4.7x	56.10+22.2x	33.94	N/A	11.47	N/A
Debt-to-Equity	0.030.0x	0.020.0x	0.020.0x	0.020.0x	0.030.0x	0.03-0.1x	0.10-0.1x	0.23

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Foghorn Therapeutics Inc. FHTX

$356.3M

Lineage Cell The LCTX

$280.7M

Alector ALEC

$261.3M

Annexon, Inc. ANNX

$995.3M

Lexeo Therapeutics Inc LXEO

$398.7M

Where Monopar Therapeutics Inc Ranks

Frequently Asked Questions

What is Monopar Therapeutics Inc's annual revenue?

Monopar Therapeutics Inc (MNPR) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Monopar Therapeutics Inc profitable?

No, Monopar Therapeutics Inc (MNPR) reported a net income of -$13.7M in fiscal year 2025.

What is Monopar Therapeutics Inc's return on equity (ROE)?

Monopar Therapeutics Inc (MNPR) has a return on equity of -10.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Monopar Therapeutics Inc's operating cash flow?

Monopar Therapeutics Inc (MNPR) recorded an outflow of $12.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Monopar Therapeutics Inc's total assets?

Monopar Therapeutics Inc (MNPR) had $140.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Monopar Therapeutics Inc spend on research and development?

Monopar Therapeutics Inc (MNPR) invested $9.9M in research and development during fiscal year 2025.

Does Monopar Therapeutics Inc buy back shares?

Yes, Monopar Therapeutics Inc (MNPR) spent $35.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Monopar Therapeutics Inc have outstanding?

Monopar Therapeutics Inc (MNPR) had 7M shares outstanding as of fiscal year 2025.

What is Monopar Therapeutics Inc's current ratio?

Monopar Therapeutics Inc (MNPR) had a current ratio of 51.35 as of fiscal year 2025, which is generally considered healthy.

What is Monopar Therapeutics Inc's debt-to-equity ratio?

Monopar Therapeutics Inc (MNPR) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Monopar Therapeutics Inc's return on assets (ROA)?

Monopar Therapeutics Inc (MNPR) had a return on assets of -9.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Monopar Therapeutics Inc's Altman Z-Score?

Monopar Therapeutics Inc (MNPR) has an Altman Z-Score of 155.81, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Monopar Therapeutics Inc's Piotroski F-Score?

Monopar Therapeutics Inc (MNPR) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Monopar Therapeutics Inc's earnings high quality?

Monopar Therapeutics Inc (MNPR) reported a net loss of $13.7M while operations used $12.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.